Pharmaceutical News

RSS

Eli Lilly to appeal against U.S. District Court ruling in Strattera patent litigation

Eli Lilly and Company today announced that the U.S. District Court for the District of New Jersey has ruled against the company in its patent litigation for Strattera. In the case of Eli Lilly and Company v. Actavis Elizabeth LLC, et al, the court ruled that Lilly's '590 patent, or method-of-use patent, for Strattera is invalid. The patent had been set to expire in May of 2017.

13 Aug 2010

UMass Memorial selects McKesson's CytoCare robot to automate compounding of hazardous IV drugs

UMass Memorial Medical Center in Massachusetts has selected the CytoCare™ robot from McKesson to automate the compounding of intravenous (IV) drugs. The robotic technology will enable the 830-bed facility to more safely prepare hazardous IVs, protecting both their patients and their staff from exposure risks.

13 Aug 2010

Study identifies use of acetaminophen may increase asthma symptoms in adults

New evidence linking the use of acetaminophen to development of asthma and eczema suggests that even monthly use of the drug in adolescents may more than double risk of asthma in adolescents compared to those who used none at all; yearly use was associated with a 50 percent increase in the risk of asthma.

13 Aug 2010

Mass. docs will soon track patients who abuse prescription drugs; Wis. Catholic Church employees now eligible for birth control

The Boston Globe: "With a few computer keystrokes, Massachusetts physicians will soon be able to identify patients who travel from clinic to clinic in pursuit of potent prescription drugs that feed lethal addictions. State health regulators yesterday unanimously approved the new detection system designed to stop 'doctor shopping' by addicted patients who try to dupe doctors into prescribing narcotics. The practice, specialists said, has fueled a surge in drug-related deaths in Massachusetts" (Smith, 8/12).

13 Aug 2010

Prices drop for PBMs; Pharmacy lobby opposes survey regarding Medicaid prices

Prices are falling for major pharmacy benefit managers, such as Medco and CVS Caremark, as the firms compete for clients, but the falling rates "don't appear to be sliding into a frenzy of unreasonable pricing," The Wall Street Journal reports. "In the current 'selling season,' when PBMs look to sign customers for the following year, discounts on new contracts have deepened by one or two percentage points, on average, from a year ago.

13 Aug 2010

Cancer Research Technology grants Valirx global rights to develop VAL 201 for cancer treatment

Cancer Research Technology has signed a deal to provide biotech company ValiRx plc with the global rights to develop a promising compound to treat hormone-resistant prostate cancer.The compound, now called VAL 201, has been shown in pre-clinical tests in mice to stop growth of tumours which have been unresponsive to hormone treatments. VAL 201 blocks genes which can cause prostate cancer to develop. The compound has been shown to be effective in treating mice with breast and prostate cancer and is now rapidly progressing towards the first clinical trials in patients.

13 Aug 2010

Tracking heart rate can provide important marker of health issues: Research

An elevated resting heart rate that develops or persists during follow-up is associated with a significantly increased risk of death, whether from heart disease or other causes, researchers from the Ronald O. Perelman Heart Institute at NewYork-Presbyterian Hospital/Weill Cornell Medical Center found studying outcomes in more than 9,000 patients.

13 Aug 2010

Study examines comparative value of different blood pressure lowering medications

Expensive brand-name medications to lower blood pressure are no better at preventing cardiovascular disease than older, generic diuretics, according to new long-term data from a landmark study.Paul Whelton, MB, MD, MSc, reported the results on Aug. 13 at the plenary session of the China Heart Congress and International Heart Forum in Beijing. Whelton is president and CEO of Loyola University Health System and chairman of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heat Attack Trial (ALLHAT), which has examined the comparative value of different blood pressure-lowering medications.

13 Aug 2010

Antares Pharma second-quarter total revenue increases 78% to $3.1 million

Antares Pharma, Inc. today reported financial and operating results for the second quarter ended June 30, 2010.

13 Aug 2010

Fast food outlets can provide statin drugs to help customers neutralise heart disease: Researchers

Fast food outlets could provide statin drugs free of charge so that customers can neutralise the heart disease dangers of fatty food, researchers at Imperial College London suggest in a new study published this week.

12 Aug 2010

Aeterna Zentaris second-quarter revenues decrease to $5.6 million

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, today reported financial and operating results for the second quarter ended June 30, 2010.

12 Aug 2010

Amorfix first-quarter fiscal 2011 net loss from operations increases to $1,724,745

Amorfix Life Sciences, a product development company focused on misfolded protein diseases, today announced its operational and financial results for the three months ended June 30, 2010.

12 Aug 2010

Pharmasset receives fast track designation from FDA for PSI-7977

Pharmasset, Inc. has received fast track designation from the U.S. Food and Drug Administration for PSI-7977 for the treatment of chronic hepatitis C virus infection. PSI-7977 is an oral uridine nucleotide analog polymerase inhibitor of HCV. Pharmasset recently completed dosing in a 28 day Phase 2a trial to evaluate PSI-7977 in combination with Pegasys (pegylated interferon) plus Copegus (ribavirin) in treatment-naive patients chronically infected with HCV genotype 1.

12 Aug 2010

Labopharm second-quarter total revenue increases to $6.8 million

Labopharm Inc. today reported its financial results for the second quarter and first six months ended June 30, 2010. All figures are in Canadian dollars unless otherwise stated.

12 Aug 2010

NextWave Pharmaceuticals, Tris Pharma sign agreement to enhance CNS product portfolio

NextWave Pharmaceuticals and Tris Pharma, both privately held companies, announced a new collaboration agreement to enhance NextWave's CNS product portfolio utilizing Tris Pharma's unique drug delivery technology for liquid and solid formulations. Tris has reacquired the rights to non CNS products including all the OTC products previously licensed to NextWave Pharmaceuticals.

12 Aug 2010

International cultivator wins Canada's prestigious medical marijuana quality award

An internationally-respected hydroponics medical marijuana cultivation educator won Canada's most prestigious medical marijuana quality award during a Toronto hydroponics expo competition...and he used a brand new type of hydroponics nutrients to do it.

12 Aug 2010

FDA advisory committee votes in favor of Ezogabine

The U.S. Food and Drug Administration advisory committee voted unanimously that clinical studies had provided substantial evidence of the effectiveness of Ezogabine (known as Retigabine outside of the U.S.) as adjunctive treatment for adults with partial-onset seizures.

12 Aug 2010

Bristol-Myers Squibb, ACTF announce enhanced agreement to support ADAPs

Bristol-Myers Squibb Company and the ADAP Crisis Task Force today announced an enhanced agreement to support the efforts of AIDS Drug Assistance Programs to provide antiretroviral medicines to people living with HIV and AIDS. Building on an agreement signed in March of 2010, today's announcement marks a multi-year enhancement to assist ADAPs in meeting the challenges of increasing patient case loads and strained government funding.

12 Aug 2010

Simcere subsidiary receives Chinese SFDA approval to manufacture and market Palonosetron

Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that its subsidiary company Simcere Dongyuan Pharmaceutical Co., Ltd. has recently received SFDA new drug certification and registration approval to manufacture and market Palonosetron material and injections in China.

12 Aug 2010

Wound Management Technologies introduces CellerateRX wound care collagen product in South Africa

Wound Management Technologies, Inc. is pleased to announce the sales expansion of its advanced wound care collagen product, CellerateRX, into South Africa. With EWA Government Systems and Spiramed (Pty) Ltd., the Company has obtained the registration of the product in the region and has also obtained the necessary NAPPI codes, which are a pre-requisite for any billable health product in South Africa. In addition, CellerateRX® is registered with various South African insurance companies and is an authorized product for reimbursement.

12 Aug 2010

Pharmaceutical News

Eli Lilly to appeal against U.S. District Court ruling in Strattera patent litigation

UMass Memorial selects McKesson's CytoCare robot to automate compounding of hazardous IV drugs

Study identifies use of acetaminophen may increase asthma symptoms in adults

Mass. docs will soon track patients who abuse prescription drugs; Wis. Catholic Church employees now eligible for birth control

Prices drop for PBMs; Pharmacy lobby opposes survey regarding Medicaid prices

Cancer Research Technology grants Valirx global rights to develop VAL 201 for cancer treatment

Tracking heart rate can provide important marker of health issues: Research

Study examines comparative value of different blood pressure lowering medications

Antares Pharma second-quarter total revenue increases 78% to $3.1 million

Fast food outlets can provide statin drugs to help customers neutralise heart disease: Researchers

Aeterna Zentaris second-quarter revenues decrease to $5.6 million

Amorfix first-quarter fiscal 2011 net loss from operations increases to $1,724,745

Pharmasset receives fast track designation from FDA for PSI-7977

Labopharm second-quarter total revenue increases to $6.8 million

NextWave Pharmaceuticals, Tris Pharma sign agreement to enhance CNS product portfolio

International cultivator wins Canada's prestigious medical marijuana quality award

FDA advisory committee votes in favor of Ezogabine

Bristol-Myers Squibb, ACTF announce enhanced agreement to support ADAPs

Simcere subsidiary receives Chinese SFDA approval to manufacture and market Palonosetron

Wound Management Technologies introduces CellerateRX wound care collagen product in South Africa

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News